The race for the tiniest waist just got even more competitive.
asserted
race → get → waist
New clinical trial results suggest a Chinese-made weight-loss drug could help people shed nearly 18% of their body weight in under a year.
uncertain
people → suggest → year
The findings suggest the newcomer could one day outperform some of the biggest names in the booming GLP-1 market, including Wegovy and Mounjaro.
uncertain
newcomer → suggest → Wegovy
In the 48-week trial, researchers from Fudan University in Shanghai recruited 567 adults who were overweight or obese and divided them into four groups.
asserted
who → recruit → groups
Three groups received weekly injections of ribupatide at doses of 2 milligrams, 4 milligrams or 6 milligrams, while the fourth received a placebo.
asserted
fourth → receive → placebo
Behind the experimental drug is Chinese pharmaceutical giant Hengrui, which partnered with US biotech firm Kailera Therapeutics to bring ribupatide to markets outside China.
asserted
which → partner → China
Ribupatide works by mimicking two hormones naturally produced in the gut that help regulate appetite, digestion and blood sugar.
asserted
that → work → appetite
It’s a similar approach to that used by Eli Lilly’s blockbuster drugs Mounjaro and Zepbound.
asserted
It → ’ → drugs
But ribupatide has been designed to bind more tightly to its targets and stay active in the body longer, potentially extending its effects throughout the week.
asserted
ribupatide → design → week
Everyone in the study — including those given placebo shots — also followed a lifestyle program that included dietary counseling and recommendations to get at least 150 minutes of moderate exercise each week.
asserted
that → include → exercise
After 48 weeks, those taking the lowest dose of ribupatide had lost an average of 10.7% of their starting body weight.
asserted
those → take → weight
Those on the 4-milligram dose shed 16.4%, while participants taking the highest dose lost a whopping 17.7%.
asserted
participants → shed → %
The placebo group lost just 1.4%.
asserted
group → lose → %
The numbers are in the same ballpark as — and potentially higher than — those seen with Wegovy.
asserted
numbers → see → Wegovy
In a separate clinical trial, people taking a 2.4 mg dose of the popular GLP-1 shot lost an average of 14.9% of their body weight over a longer period of 68 weeks.
asserted
people → take → weeks
Weight loss hadn’t started to level off among participants taking the two highest doses by the end of the 11-month study, suggesting they could have lost even more with longer treatment.
uncertain
they → start → treatment
And the benefits extended beyond the scale.
asserted
benefits → extend → scale
Although none of the participants had diabetes, researchers found that those taking ribupatide had reductions in blood sugar.
asserted
those → have → sugar
They also saw improvements in blood pressure and cholesterol.
asserted
They → see → pressure
Their waistlines shrank, too — an important measurement because abdominal fat is linked to an increased risk of heart disease and other health problems.
asserted
fat → shrink → disease
The participants taking ribupatide saw their waist measurements drop by between 9 and 14 centimeters, compared with just 2.5 centimeters among those on the placebo.
asserted
measurements → take → placebo
Like other GLP-1s, ribupatide most commonly caused digestive problems, including nausea, vomiting and diarrhea.
asserted
ribupatide → cause → nausea
The researchers said the symptoms were generally mild to moderate and occurred most often as participants increased their doses.
asserted
participants → say → doses
Study authors said their results are promising and come amid a need for more pharmacological treatment options as obesity continues to plague millions of people.
asserted
obesity → say → people
The problem is particularly acute in the US, where roughly four in 10 adults have obesity and an even larger share are overweight.
asserted
share → have → obesity
Among children and teenagers ages 2 to 19, just over 21% have obesity.
asserted
% → have → obesity
It’s no wonder Americans’ appetite for weight-loss injections shows little sign of slowing.
asserted
appetite → ’ → slowing
A September Gallup survey found that 11% of US adults were currently taking a GLP-1 medication for weight loss, up from just 3% in 2024.
asserted
% → find → 2024
Overall, 15% said they had taken one of the blockbuster drugs at some point in their lives — a jump of nine percentage points in just two years.
asserted
they → say → years